Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the ...

Results from the NRG Oncology Phase II NRG-GOG-0279 clinical study indicate that women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin ...

Please provide your email address to receive an email when new articles are posted on . Risk for late feeding tube dependence was low and did not differ between intensity-modulated radiation therapy ...

Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...

Phase II trial of capecitabine (CAP) and oxaliplatin (OX) in patients (pts) with adeno- and undifferentiated carcinoma of unknown primary (CUP) No significant financial relationships to disclose. This ...

SINGAPORE -- Intensity-modulated radiation therapy (IMRT) should be the radiation technique of choice for unresectable locally advanced non-small lung cancer (NSCLC), a secondary analysis of a ...

According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved ...

The CHRISTUS St. Patrick Hospital Regional Cancer Center has unveiled the most advanced approach to what is known as 3D conformal radiation therapy. One of the most exciting recent developments in ...

The use of intensity-modulated radiation therapy (IMRT) and the addition of gemcitabine to cisplatin increased the complete pathologic response (CPR) in women with locally advanced squamous cell ...

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...